U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Non-Cutaneous Melanoma

MedGen UID:
1793140
•Concept ID:
C5556699
•
Neoplastic Process

Definition

Non-cutaneous melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Non-Cutaneous Melanoma

Professional guidelines

PubMed

Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL, Johansson PA, Nathan V, Howlie M, Symmons J, Palmer JM, Hayward NK
PLoS One 2018;13(4):e0194098. Epub 2018 Apr 11 doi: 10.1371/journal.pone.0194098. PMID: 29641532Free PMC Article
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255

Recent clinical studies

Etiology

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q, Ding Y, Zhang X, Li J
J Cancer Res Clin Oncol 2023 Feb;149(2):701-708. Epub 2022 Dec 1 doi: 10.1007/s00432-022-04377-4. PMID: 36454283
Association of advanced age and cancer history with autoimmune disease in melanoma patients: a cross-sectional study.
Holmes AN, Swede H, Feer WM, Pike DC, Wang X, Hegde UP
BMC Cancer 2021 Dec 6;21(1):1300. doi: 10.1186/s12885-021-09001-1. PMID: 34872504Free PMC Article
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255

Diagnosis

Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape.
Vergara IA, Wilmott JS, Long GV, Scolyer RA
Exp Dermatol 2022 Jan;31(1):13-30. Epub 2021 Feb 1 doi: 10.1111/exd.14287. PMID: 33455025
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Clinico-pathological Characteristics of Cutaneous Malignant Melanoma in Pakistan.
Khan RS, Shakeel O, Bhatti AF, Hussain R
J Coll Physicians Surg Pak 2020 Nov;30(11):1197-1200. doi: 10.29271/jcpsp.2020.11.1197. PMID: 33222740
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL, Johansson PA, Nathan V, Howlie M, Symmons J, Palmer JM, Hayward NK
PLoS One 2018;13(4):e0194098. Epub 2018 Apr 11 doi: 10.1371/journal.pone.0194098. PMID: 29641532Free PMC Article
Clinicopathologic features and prognostic factors in patients with non-cutaneous malignant melanoma: a single-center retrospective study of 71 cases.
Zhu H, Dong D, Li F, Liu D, Wang L, Fu J, Song L, Xu G
Int J Dermatol 2015 Dec;54(12):1390-5. Epub 2015 May 27 doi: 10.1111/ijd.12745. PMID: 26016703

Therapy

Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL, Johansson PA, Nathan V, Howlie M, Symmons J, Palmer JM, Hayward NK
PLoS One 2018;13(4):e0194098. Epub 2018 Apr 11 doi: 10.1371/journal.pone.0194098. PMID: 29641532Free PMC Article
Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.
Trinh VA, Joseph J, Hwu WJ
Discov Med 2018 Jan;25(135):31-40. PMID: 29466692
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255

Prognosis

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q, Ding Y, Zhang X, Li J
J Cancer Res Clin Oncol 2023 Feb;149(2):701-708. Epub 2022 Dec 1 doi: 10.1007/s00432-022-04377-4. PMID: 36454283
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL, Johansson PA, Nathan V, Howlie M, Symmons J, Palmer JM, Hayward NK
PLoS One 2018;13(4):e0194098. Epub 2018 Apr 11 doi: 10.1371/journal.pone.0194098. PMID: 29641532Free PMC Article
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255
Clinicopathologic features and prognostic factors in patients with non-cutaneous malignant melanoma: a single-center retrospective study of 71 cases.
Zhu H, Dong D, Li F, Liu D, Wang L, Fu J, Song L, Xu G
Int J Dermatol 2015 Dec;54(12):1390-5. Epub 2015 May 27 doi: 10.1111/ijd.12745. PMID: 26016703

Clinical prediction guides

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, Cheung WY, Heng DYC, Cheng T
Curr Oncol 2023 Sep 30;30(10):8936-8947. doi: 10.3390/curroncol30100646. PMID: 37887546Free PMC Article
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Clinico-pathological Characteristics of Cutaneous Malignant Melanoma in Pakistan.
Khan RS, Shakeel O, Bhatti AF, Hussain R
J Coll Physicians Surg Pak 2020 Nov;30(11):1197-1200. doi: 10.29271/jcpsp.2020.11.1197. PMID: 33222740
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL, Johansson PA, Nathan V, Howlie M, Symmons J, Palmer JM, Hayward NK
PLoS One 2018;13(4):e0194098. Epub 2018 Apr 11 doi: 10.1371/journal.pone.0194098. PMID: 29641532Free PMC Article
Clinicopathologic features and prognostic factors in patients with non-cutaneous malignant melanoma: a single-center retrospective study of 71 cases.
Zhu H, Dong D, Li F, Liu D, Wang L, Fu J, Song L, Xu G
Int J Dermatol 2015 Dec;54(12):1390-5. Epub 2015 May 27 doi: 10.1111/ijd.12745. PMID: 26016703

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...